Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors

作者：James L. Rogers, Thomas C. Wall, Alvina Acquaye-Mallory, Lisa Boris, Yeonju Kim, Kenneth Aldape, Martha Quezado, John A. Butman, James G. Smirniotopoulos, Huma Chaudhry, Christina Tsien, Prashant Chittiboina, Kareem A. Zaghloul, Orwa Aboud, Nicholas G. Avgeropoulos, Eric Burton, David Cachia, Karan Dixit, Jan Drappatz, Erin Dunbar, Peter Forsyth, Edina Komlódi-Pásztor, Jacob Mandel, Byram H. Ozer, Eudocia Q. Lee, Surabhi Ranjan, Rimas V. Lukas, Margarita Raygada, Michael Salacz, Matthew Smith-Cohn, James M. Snyder, Ariane Soldatos, Brett Theeler, Brigitte C. Widemann, Kevin Camphausen, John D. Heiss, Terri S. Armstrong, Mark R. Gilbert, Marta Peñas-Prado · 发表于：Journal of Neuro-Oncology · 年份：2024 · DOI：10.1007/s11060-024-04613-6 · 被引用次数：8 · 研究领域：Glioma Diagnosis and Treatment、Brain Metastases and Treatment、Meningioma and schwannoma management

PURPOSE: Multidisciplinary tumor boards (MTBs) integrate clinical, molecular, and radiological information and facilitate coordination of neuro-oncology care. During the COVID-19 pandemic, our MTB transitioned to a virtual and multi-institutional format. We hypothesized that this expansion would allow expert review of challenging neuro-oncology cases and contribute to the care of patients with limited access to specialized centers. METHODS: We retrospectively reviewed records from virtual MTBs held between 04/2020-03/2021. Data collected included measures of potential clinical impact, including referrals to observational or therapeutic studies, referrals for specialized neuropathology analysis, and whether molecular findings led to a change in diagnosis and/or guided management suggestions. RESULTS: During 25 meetings, 32 presenters discussed 44 cases. Approximately half (n = 20; 48%) involved a rare central nervous system (CNS) tumor. In 21% (n = 9) the diagnosis was changed or refined based on molecular profiling obtained at the NIH and in 36% (n = 15) molecular findings guided management. Clinical trial suggestions were offered to 31% (n = 13), enrollment in the observational NCI Natural History Study to 21% (n = 9), neuropathology review and molecular testing at the NIH to 17% (n = 7), and all received management suggestions. CONCLUSION: Virtual multi-institutional MTBs enable remote expert review of CNS tumors. We propose them as a strategy to facilitate expert opinions ...